Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Akari Therapeutics PLC (AKTX : NSDQ)
 
 • Company Description   
Akari Therapeutics PLC is a biopharmaceutical company. It focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. The Company's lead drug consist of Coversin is a recombinant small protein, which acts on complement component-C5, preventing release of C5a and formation of C5b-9. Akari Therapeutics PLC, formerly known as Celsus Therapeutics Plc, is based in London, United Kingdom.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.09 Daily Weekly Monthly
20 Day Moving Average: 55,379 shares
Shares Outstanding: 59.35 (millions)
Market Capitalization: $64.69 (millions)
Beta: 1.24
52 Week High: $1.89
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.63% 4.04%
12 Week -11.38% -2.57%
Year To Date -27.33% -11.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
75/76 WIMPOLE STREET
-
LONDON,X0 W1G 9RT
GBR
ph: 44-20-8004-0270
fax: 646-843-9352
info@akaritx.com http://www.akaritx.com
 
 • General Corporate Information   
Officers
Clive Richardson - Chief Executive Officer and Chief Operating Office
Ray Prudo - Executive Chairman
Torsten Hombeck - Chief Financial Officer
James Hill - Director
Stuart Ungar - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00972G108
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 07/05/22
Share - Related Items
Shares Outstanding: 59.35
Most Recent Split Date: 9.00 (0.10:1)
Beta: 1.24
Market Capitalization: $64.69 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 10.19
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 45.45%
vs. Previous Quarter: -300.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -281.03
ROA
03/31/22 - -
12/31/21 - -
09/30/21 - -175.82
Current Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 4.38
Quick Ratio
03/31/22 - -
12/31/21 - -
09/30/21 - 4.38
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -
09/30/21 - 0.24
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©